###### Key questions

What is already known about this topic?
=======================================

-   Environmental enteric dysfunction (EED) is a disorder of the small bowel affecting populations living in conditions of poor sanitation and hygiene.

-   EED leads to chronic malnutrition and stunting, which affects 26% of children \<5 years of age in the developing world and leads to 21% of deaths in this age group.

-   There is a critical need for a reliable, simple, non-invasive and sensitive biomarker of disease activity to potentially identify in the field high-risk individuals who are candidates for interventional trials.

-   The current application of the lactulose/mannitol assay inconsistently identifies at-risk or affected patients from endemic populations.

What are the new findings?
==========================

-   We demonstrate a novel method that refines the saccharide intestinal permeability assay through the choice of monosaccharide, the method of detection, the timing of urine collection and the dose of analytes.

-   We provide normative values of the lactulose/rhamnose permeability assay in healthy infants.

-   We document evidence for increased intestinal permeability in two cohorts of children from populations in which EED is endemic.

-   The method described has the potential to provide consistent test performance in the field for the detection of impaired intestinal barrier integrity in EED and selection of patients for therapeutic trials.

Recommendations for policy
==========================

-   We recommend the use of rhamnose over mannitol when performing the saccharide intestinal permeability assay given the significant environmental contamination of the latter.

-   We recommend the reporting of both test analytes (over simply a ratio), as saccharide intestinal absorption reflects complex intestinal physiology related to both permeability and loss of surface area.

-   When using high-performance liquid chromatography with tandem mass spectrometry as the saccharide quantification methodology, a shortened 60--90 min urine collection window may lead to a more focused evaluation of small bowel permeability and enhanced test performance.

Introduction {#s1}
============

Environmental enteric dysfunction (EED) is a disorder of the small bowel affecting populations living in conditions of poor sanitation and hygiene.[@R1] It is hypothesised that repetitive intestinal infection results in chronic intestinal inflammation, villous atrophy, malabsorption and linear growth failure. EED is a putative underlying cause of chronic malnutrition and stunting, which affects 26% of children under 5 years of age in the developing world and is associated with 21% of deaths in this age group (<http://www.un.org/millenniumgoals>). Poor nutrition is associated with cognitive stunting with implications for future socioeconomic status.[@R2] EED may also explain the reduced efficacy of oral vaccines in low income and middle income countries and the increased risk of serious infection in children with undernutrition.[@R3] [@R4] Thus, there is a critical need for a reliable, simple, non-invasive and sensitive biomarker of disease activity to potentially identify in the field high-risk individuals who are candidates for interventional trials.

Saccharide-based permeability assays (eg, lactulose/mannitol) have been widely used in malabsorptive conditions; however, the current application of the lactulose/mannitol assay inconsistently identifies at-risk or affected patients from endemic populations.[@R5] Potential limitations in test performance include the enzymatic method to measure the saccharides, the timing of urine collection and the test saccharides chosen. The standard 5-hour urine collection period has led to the unclear relationship between probe concentration and permeability of different gastrointestinal (GI) tract segments. Finally, since mannitol was identified at baseline (before oral administration of the test sugar) among adults studied in the USA in up to 30% of participants,[@R6] significant concerns exist regarding contributions to the analyte in the collected sample by the same saccharide from non-probe sources. The monosaccharide L-rhamnose is a hydrophilic deoxy sugar of similar molecular weight and volume (by van der Walls surface) as mannitol, but it is less widely used in food and other materials and is therefore an alternative candidate for evaluation of malabsorption and intestinal permeability.

Our study aim was to address the principal limitations of the current LM test and prospectively compare intestinal barrier function in infants with EED from at-risk populations on two continents (age below 37 months) with healthy control infants (2--13 months of age) from the USA. We describe a standardised method including administration protocol, consistent urine collection applicable at points of care in the field, and a reliable assay that can be performed at a centralised laboratory using liquid chromatography-mass spectrometry. The sensitivity and accuracy of this analytical chemistry approach has allowed our laboratory to reduce (by a factor of 5) the administered doses of rhamnose and lactulose, a change that both makes the test easier to tolerate and more likely to proceed without confounding by major alterations of intestinal motility and transit.[@R7] Furthermore, by shortening the time of urine collection, the permeability deficits documented are more likely a result of permeability in the small bowel where EED changes are thought to occur and also make the test easier to perform in the resource limited settings.

Methods {#s2}
=======

Participants {#s2a}
------------

Olmsted County, MN: Healthy infants between 2 and 13 months of age (n=27) were recruited from the outpatient practice at Mayo Clinic, Olmsted County, Minnesota, USA. These children were recruited at well-child visits during routine preventative care (2, 4, 6, 9 and 12 months). Age (months), length (cm) and weight (kg) were recorded. Additional metadata recorded included the time of last oral intake, current medications or symptoms within previous 48 hours to the study visit.

Lusaka, Zambia: Children between 2 and 36 months (n=85) were recruited from one sector of the Misisi township in Lusaka, the capital of Zambia. Misisi compound is a district of southern Lusaka in which studies of EED have been conducted since 1999.[@R8]

Loreto, Peru: A second cohort (n=19) of patients from an EED region (age range 15--29 months) was recruited from three rural communities in the Department of Loreto, 15 km southeast of Iquitos, Peru. Studies of EED have been performed there since 2009.[@R9]

Eligibility criteria {#s2b}
--------------------

Children with concurrent illness or who had had diarrhoea within 1 month, or who had been given antibiotics within 1 month were excluded from study. Patients with a positive stool sample for ova and parasites at least 7 days prior to the study received treatment prior to the saccharide assay.

Ethical committee approval {#s2c}
--------------------------

Approval for the study was obtained from the University of Zambia Biomedical Research Ethics Committee (006-01-13, 11 April 2013) and the Institutional Review Board of the John\'s Hopkins Bloomberg School of Public Health and the Ethics Committee of Asociacion Benefica PRISMA in Lima, Peru.[@R9] The study was approved by the Mayo Clinic Institutional Review Board (12-003757, approved 18 April 2012), and informed consent was obtained by the parent(s) or legal guardian(s).

Urine collection protocol {#s2d}
-------------------------

The clinical protocol including saccharide administration, timing of urine collection and anthropometric data collection was identical across the three sites. The reagents were purchased from TCI chemicals, Portland, Oregon (USA and Peru) and Sigma-Aldrich, St Louis, Missouri, USA (Zambia). Aliquots of frozen urine were shipped on dry ice to the ICL at Mayo Clinic. Urine samples were collected pre dosing and post dosing.

Administration of sugars {#s2e}
------------------------

The oral solution consisted of 200 mg monosaccharide (L-rhamnose, TCI product code R0013, Portland, Oregon, USA) and 1000 mg disaccharide (lactulose, TCI product code L0140 Portland, Oregon, USA) in 10 mL sterile water. Study personnel administered the entire solution over a period of 5 min to the infant. Annotations were collected for notable issues during dosing (infant spitting up, refusal, etc).

Post-dose urine collection {#s2f}
--------------------------

The urine bag was placed on the infant 30 min post dosing and collected over the subsequent 60 min (30--90 min post dosing). Oral intake (water, breast milk, formula, no solid foods) after administration of sugar solution was encouraged with a goal of 4 mL/kg intake over 30 min to promote urine production. If no urine was present at the end of 60 min, the collection was continued until urine was present in the bag but no longer than an additional 30 min.

Samples were labelled with participant study ID and with a pre-dose or post-dose tag. Samples were stored at −20°C until analysis. Batched samples were placed on dry ice and delivered to the Immunochemical Core Laboratory (ICL) at Mayo Clinic for analysis.

Methodology of HPLC MS:MS {#s2g}
-------------------------

The methodology was performed as recently published with the following modifications to account for the molecular weight transition for rhamnose.[@R6] The following transitions were monitored: mannitol analyte (181.05/89), ^13^C(6) mannitol IS (186.9/60.9), lactulose analyte (341/101) ^13^C(12) lactulose I.S. (353/167), rhamnose analyte (163/58.8). The rhamnose analyte was quantified using the mannitol I.S. Mannitol, lactulose and rhamnose were used to make the standard curves and the sources for the internal standard were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Analytical validation of the assay is included in online [supplementary materials](#SM1){ref-type="supplementary-material"}.
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Statistical analysis {#s2h}
--------------------

Patient characteristics within each population were summarised using the median and range for continuous measures. Categorical measures were summarised as counts and percentages. Fractional recovery of rhamnose and lactulose levels across the three cohorts was assessed using the Kruskal-Wallis test. Post-dosing concentrations of rhamnose and lactulose as well as the lactulose: rhamnose ratio (LRR) and anthropomorphic measures were compared in the three groups using the Kruskal-Wallis test. Detectable urinary rhamnose (concentration \>1.0 µg/mL) in the post dosing urine specimen was required to consider the test evaluable. The 95th centile of the LRR in the US cohort was defined a priori as the maximum for a normal, healthy population.

Weight-for-age Z scores (WAZ) and height-for-age Z scores (HAZ) were compared with post-dose lactulose in scatterplots showing the study cohort (symbol) and quartile of post-dose rhamnose (colour). Linear regression was used to predict WAZ scores and HAZ scores with post-dose lactulose, post-dose rhamnose and the interaction of these two predictors in two separate models. All analyses were performed using the SAS software (V.9.4, SAS Institute, Cary, North Carolina, USA).

Sample size calculation {#s2i}
-----------------------

The coefficient of variation for the assay of Mannitol and Lactulose in adult healthy participants is 33% and 50%, respectively. Detectable difference with n=12 per group (eg, healthy vs EED) would have 80% power to detect a difference in rhamnose excretion of 40% and in lactulose excretion of 58%. These predictions were based on a \>600% increase in L:M ratio in Crohn\'s disease (0.054±0.060 in health vs 0.323±0.253 in Crohn\'s disease).[@R10] Furthermore, in irritable bowel syndrome (IBS), which is typically associated with diarrhoea, there is at least a twofold increase in small intestinal permeability relative to controls and IBS associated with constipation; small intestinal permeability was increased in IBS (0.19 (0.12--0.23)) in contrast to constipated IBS (0.085 (0.043--0.13)) and controls (0.07 (0.035--0.19)).[@R11]

Results {#s3}
=======

Subject demographics {#s3a}
--------------------

The age and anthropometric data including median height/length and weight-for-age z-scores (HAZ and WAZ, respectively) of the three cohorts are included in [table 1](#BMJGH2016000066TB1){ref-type="table"}. Children from Peru (n=19) and Zambia (n=85) were older when compared to the US healthy population (n=27). Median (range) WAZ and HAZ in the Peruvian cohort (WAZ: −0.8 (−2.7, 0.8); HAZ: −1.8 (−3.3, −0.2)) and the Zambian cohort (WAZ: −1.4 (−4.0, 1.1); HAZ: −2.3 (−8.5, 1.2)) were significantly different from that in the US cohort (WAZ: 0.5 (−0.4, 2.1), p\<0.001; HAZ: −0.1 (−1.8, 2.4), p\<0.001, [table 1](#BMJGH2016000066TB1){ref-type="table"}). Thus, while the cohorts of children from regions endemic for EED were not overtly ill, anthropometric indices suggested that they were representative of affected children with EED in these populations.

###### 

Demographic characteristics for the study cohorts from the USA, Peru and Zambia

                                           USA (N=27)           Peru (N=19)           Zambia\* (N=85)
  ---------------------------------------- -------------------- --------------------- ---------------------
  Age (months), median (range)             8.0 (2.0 to 13.0)    27.0 (15.0 to 29.0)   21.0 (12.0 to 36.0)
  Gender, N (%)                                                                       
   F                                       8 (30)               8 (42)                45 (63)
   M                                       19 (70)              11 (58)               27 (38)
  Height-for-age z-score, median (range)   −0.1 (−1.8 to 2.4)   −1.8 (−3.3 to −0.2)   −2.3 (−8.5 to 1.2)
  Weight-for-age z-score, median (range)   0.5 (−0.4 to 2.1)     −0.8 (−2.7 to 0.8)   −1.4 (−4.0 to 1.1)
  δ Rhamnose \<1 N (%)                     5 (19)               0 (0)                 12 (14)

\*In the Zambian cohort, age was available on 73 participants while gender and z-scores were available on 72 participants.

Feasibility of urine saccharide absorption test {#s3b}
-----------------------------------------------

The infants from all three cohorts followed the standard protocol of sugar administration (see methods). Evaluable tests were seen in 22/27 US infants (81%), 19/19 Peruvian children (100%) and 73/85 Zambian children (86%). In the US cohort, regurgitation of saccharide solution or urine collection bag failure (leak) was the primary cause of test failure (5 cases compared to 22 successful test applications). Similar metadata was not available from Zambia to determine the primary causes of test failure. The median (range) of total urine volume collected (mL) was 13.4 (1.3, 65.1), 21.5 (7.0, 67.0) and 5.0 (0.5, 10.0) in the US, Peruvian and Zambian cohorts, respectively.

Baseline urinary levels of mannitol {#s3c}
-----------------------------------

Detectable concentrations of mannitol were present in over 90% of children in all three cohorts within the baseline urine sample. Since these samples were collected prior to saccharide dosing (and mannitol was not used as a probe), this finding indicates significant environmental contamination. The median (range) of the mannitol concentration identified prior to saccharide dosing in the cohorts from the USA, Peru and Zambia was 5.2 µg/mL (0.1, 17.3), 10.8 µg/mL (0.0, 29.7) and 10.3 µg/mL (0.8, 40.2), respectively ([table 2](#BMJGH2016000066TB2){ref-type="table"}). We assessed pre-dosed (baseline) urine samples for the presence of L-rhamnose. In all three cohorts, the presence of L-rhamnose in pre-administration urine was negligible ([table 2](#BMJGH2016000066TB2){ref-type="table"}). Indeed, there were only 3 individuals (2.6%) in the entire cohort who had pre-dosing urine levels of rhamnose and lactulose that theoretically could interfere with the interpretation of the assay results.

###### 

Median (range) of pre-dosing sugar concentrations by study cohort

                          USA (N=20)\*        Peru (N=19)          Zambia (N=63)\*      p Value†
  ----------------------- ------------------- -------------------- -------------------- ----------
  Pre-mannitol (μg/mL)    5.2 (0.1 to 17.3)   10.8 (0.0 to 29.7)   10.3 (0.8 to 40.2)   0.046
  Pre-rhamnose (μg/mL)    0.0 (0.0 to 0.4)    0.0 (0.0 to 20.1)    0.1 (0.0 to 36.9)    0.024
  Pre-lactulose (μg/mL)   0.0 (0.0 to 4.0)    0.5 (0.0 to 19.9)    0.1 (0.0 to 86.1)    0.043

\*Pre-dosing sugar data for the U.S. cohort was available for 20 of the 27 participants and for the Zambian cohort in 63 of the 85 participants.

†Kruskal-Wallis test.

Permeability measurements using fractional excretion of saccharides and lactulose: rhamnose ratio in participants at risk for EED {#s3d}
---------------------------------------------------------------------------------------------------------------------------------

Rhamnose excretion: There were no significant differences in the permeability to rhamnose as assessed by median urinary rhamnose concentrations between the three groups ([table 3](#BMJGH2016000066TB3){ref-type="table"}, [figure 1](#BMJGH2016000066F1){ref-type="fig"}). The fractional recovery of rhamnose was significantly higher in the US (0.38% (0.00%, 1.84%)) and Peruvian (0.61% (0.02%, 6.32%)) cohorts compared to the Zambian (0.07% (0.00%, 1.50%)) cohort (p\<0.001) ([table 3](#BMJGH2016000066TB3){ref-type="table"}).

###### 

Summary of sugar excretion following oral administration by study cohort

                                                            Summary of sugar excretion following oral administration by population                                                      
  --------------------------------------------------------- ------------------------------------------------------------------------ ------------------------- ------------------------ -----------
  Post-rhamnose (ug/mL), median (range)                     50.10 (0.29 to 213.00)                                                   102.00 (2.66 to 301.00)   34.50 (1.58 to 847.00)   0.354‡
  Fractional recovery rhamnose (%), median (range)          0.38 (0.00 to 1.84)                                                       0.61 (0.02 to 6.32)      0.07 (0.00 to 1.50)      0\<0.001‡
  Post-lactulose (μg/mL), median (range)                    6.78 (0.29 to 31.90)                                                     47.60 (4.23 to 379.00)    75.40 (0.67 to 873.00)   \<0.001‡
  Fractional recovery lactulose (%), median (range)          0.01 (0.00 to 0.07)                                                     0.15 (0.01 to 0.69)       0.03 (0.00 to 0.35)      \<0.001‡
  LR ratio, median (range)                                   0.14 (0.06 to 1.00)                                                     0.75 (0.15 to 5.02)       2.26 (0.08 to 14.48)     \<0.001‡
  Abnormal post LRR compared to the American 95th centile   1 (5%)                                                                   10 (53%)                  60 (82%)                 \<0.001§

\*Fractional recovery was available in 18 of the 19 Peruvian participants.

†Fractional recovery was only available in 67 of the Zambian participants. Other post-dose sugar concentrations were available for 73 of the Zambian participants.

‡Kruskal-Wallis test.

§χ^2^ Test.

![Box plot comparison of pre-dose and post-dose concentrations for rhamnose and lactulose for the three study cohorts.](bmjgh2016000066f01){#BMJGH2016000066F1}

Lactulose excretion: Significant differences in lactulose as expressed by both urine concentrations and fractional excretion were evident in the cohorts of patients from areas endemic for EED compared to the US controls ([table 3](#BMJGH2016000066TB3){ref-type="table"}, [figure 1](#BMJGH2016000066F1){ref-type="fig"}). Consistent with the lack of significant pre-dosing saccharide contamination ([table 2](#BMJGH2016000066TB2){ref-type="table"}), results were identical on analysis of δ lactulose (post-dose lactulose less pre-dose concentration, data not shown). Similar to the lactulose concentration, the fractional recovery of lactulose was significantly greater in the Zambian (0.03% (0.00%, 0.35%)) and Peruvian (0.15% (0.01%, 0.69%) cohorts when compared to the US (0.01% (0.00%, 0.07%)) cohort (p\<0.001, [table 3](#BMJGH2016000066TB3){ref-type="table"}).

Lactulose to rhamnose ratio: Given the previous experience with saccharide ratios and the challenges of urine bag collection with precise urine volume recording in the field, we calculated the lactulose to rhamnose ratio based on concentrations of the sugars (LRR). We observed significant differences in the median (range) LRR in the Peruvian (0.75 (0.15, 5.02)) and Zambian (2.26 (0.08, 14.48)) cohorts compared to the US (0.14 (0.06, 1.00)) cohort (p\<0.001) ([table 3](#BMJGH2016000066TB3){ref-type="table"}, [figure 1](#BMJGH2016000066F1){ref-type="fig"}). Using the 95th centile from the US population as the upper limit of normal, ∼53% of Peruvian children and 82% of Zambian children studied displayed abnormal LRR (p\<0.001, [table 3](#BMJGH2016000066TB3){ref-type="table"}).

Appraisal of height and weight relative to LRR {#s3e}
----------------------------------------------

Using the HAZ and WAZ scores of children at the time of LRR within the Zambian and Peruvian cohorts, we assessed the ability of WAZ and HAZ to predict abnormal LRR as defined by \>95%centile in the US cohort ([figure 2](#BMJGH2016000066F2){ref-type="fig"}). In a multivariate effect modification model in which the outcome was WAZ score ([table 4](#BMJGH2016000066TB4){ref-type="table"}), lower post-dose lactulose was associated with higher WAZ scores among children with the same level of post-dose rhamnose (p=0.0002). When children differed in rhamnose, however, those with both higher rhamnose and higher lactulose also had slightly greater WAZ scores (p=0.01) after accounting for the association between lactulose and weight for age when rhamnose was the same. In this model, 13% of the WAZ score variability among children was explained by lactulose and rhamnose excretion. A similar pattern emerged when predicting height-for-age Z scores, but the differences were not statistically significant.

![Scatterplot weight-for-age Z scores (WAZ) and height-for-age Z scores (HAZ) by post-dose lactulose and rhamnose concentration for the three study cohorts.](bmjgh2016000066f02){#BMJGH2016000066F2}

###### 

Linear regression results predicting weight-for-age and height-for-age Z scores by post-dose lactulose and rhamnose concentrations and their interaction

  Outcome variable                 Predictor                        Coefficient (95% CI)            p Value   R^2^
  -------------------------------- -------------------------------- ------------------------------- --------- ------
  Weight-for-age Z score (N=104)   Intercept                        −0.5007 (−0.9248 to 0.01766)    0.003     13%
  Post lactulose                   −0.0041 (−0.0063 to −0.002)      \<0.001                                   
  Post rhamnose                    −0.0007 (−0.0033 to 0.0017)      0.536                                     
  Lactulose-rhamnose interaction   0.000007 (0.00000 to 0.00001)    0.013                                     
  Height-for-age Z score (N=104)   Intercept                        −1.13512 (−1.5629 to −0.7075)   \<0.001   10%
  Post lactulose                   −0.0046 (−0.0074 to −0.0018)     0.0018                                    
  Post rhamnose                    −0.0008 (−0.0041 to 0.0025)      0.630                                     
  Lactulose-rhamnose interaction   0.000007 (−0.00000 to 0.00002)   0.098                                     

Discussion {#s4}
==========

EED results from the chronic inflammatory response to repetitive GI infectious insults, and thus populations living in poverty in the developing world are commonly affected to varying degrees. A general association of the lactulose to mannitol ratio, particularly in relationship to impaired linear growth, has been noted among several groups; however, significant issues remain with the test\'s performance.[@R5] We provide normative values of the lactulose/rhamnose permeability assay in healthy infants and document evidence for increased intestinal permeability in two cohorts of children from populations in which EED is endemic. These observations suggest that the method described has the potential to provide consistent test performance in the field for the detection of impaired intestinal barrier integrity in EED. Our data also suggest that there was monosaccharide (rhamnose) malabsorption (reduced absolute mass excreted and fractional recovery in urine) in at-risk children from Zambia compared to US controls, and that the stunted weight observed in the at-risk cohorts was associated with the documented measurements of monosaccharide malabsorption as well as increased intestinal permeability, which is best adjudicated on the basis of the lactulose excretion, fractional recovery of lactulose in urine and LRR. Thus, children in Zambia have evidence for both monosaccharide malabsorption and increased intestinal permeability to the larger disaccharide molecule.

Current understanding is consistent with the existence of two pore sizes in the human small intestinal epithelium, with the larger pore size (10.1 Angstrom) present in the crypts while the smaller pores are located in the villus tip.[@R12] In extensive small intestinal diseases associated with significant flattening of the villus border and resultant impairment of the surface area, it is not clear whether paracellular transport through either pore is proportionally affected and the overall effect of decreased surface area is also unclear. We observed a significantly lower recovery of the monosaccharide rhamnose in the cohort of children from Zambia when compared to the US and Peruvian cohorts. Similarly, low recovery of the monosaccharide mannitol was described in affected children in Gambia, suggesting the significant contribution of malabsorption along with altered permeability in the interpretation of saccharide permeability assays in severely affected children.[@R13] Combinatorial effects of malabsorption and altered permeability are general limitations in assessment of solute trafficking dependent on size. Indeed, the impact of mannitol excretion in driving variances in LMR across studies has been previously postulated.[@R14] We speculate that the diminished recovery of rhamnose in the Zambian cohort reflects decreased intestinal surface area related to villus blunting and a more severe phenotype, and this may compromise the assessment of the ratio of excretion of the two saccharides in the LRR. Therefore, the absolute excretion or fractional recovery of the disaccharide alone may potentially be a more accurate marker of intestinal permeability. Overall, these data emphasise the importance of separate reporting of recovery for both saccharides.

Our data suggest the growth stunting evident in the at-risk cohorts to be associated with impaired intestinal permeability as evidenced by the coefficient of determination (R^2^) of the multivariate regression model to predict weight-for-age and height-for-age z scores. One factor contributing to improved assay concordance may be the timing of urine collection. The simultaneous assessment of intestinal transit and lactulose and mannitol permeability in healthy adult participants indicates that urine collection within 2 hours of oral sugar load reflects primarily small intestinal permeability while collection beyond 8 hours reflects exclusively colonic absorption.[@R7] While equivalent data are not available in children, previous protocols have uniformly extended the collection to 5 hours during which the saccharide can reach the caecum and ascending colon in at least a subset of participants;[@R15] thus, such recovery studies may have assessed both small bowel and colonic permeability with interindividual variances related to the differences in location of the saccharides during the 5 hours of urine collection.

Finally, the regression analyses show that permeability is a marker that alone accounts for ∼13% of the variance in WAZ. Thus, other factors such as malabsorption, recurrent infection and undernutrition constitute other risk factors that most likely contribute to the low WAZ and HAZ. Nevertheless, permeability measurement constitutes a good screening test for EED in the field, and should lead to a search for concomitant risk factors or institution of interventions to restore barrier integrity, when such drugs become available.

In conclusion, we demonstrate a novel method that refines the saccharide intestinal permeability assay. The advantages of the method that we have applied in the field in Zambia and Peru are decreased dose of saccharides administered, shortened urine collection time and use of a monosaccharide without risk of significant environmental contamination. Minimal environmental contamination may lead to the lack of reliance on baseline urine samples; yet further validation with corresponding histology in a separate disease cohort (coeliac disease) is currently ongoing.
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